Dr. Garo H. Armen

Garo H. Armen has spent more than three decades operating at the intersection of science, capital, and sustainable development.

He is the founder and longtime CEO of Agenus (formerly Antigenics), a biotechnology company which Armen built from a research concept into a clinical-stage developer of cancer immunotherapies. Over thirty-plus years, Agenus has produced therapies now reaching patients with cancers that have resisted prior generations of cancer treatments.

In 2002, Dr. Armen was called in to chair Elan Corporation, an Irish pharmaceutical company whose stock had collapsed 96% amid fraud accusations that were compared to Enron by the international press. He led a billion-dollar restructuring that returned the company to viability—a turnaround now taught as a case study at the Kellogg School of Management.

In 2003 he founded the Children of Armenia Fund (COAF), a philanthropic organization that has implemented over $100 million in projects across more than 100 rural Armenian villages — rebuilding schools, establishing health clinics, and reversing years of post-Soviet decline.

He also owns and operates a working regenerative farm in Maine producing vegetables, grains, livestock, and prepared foods sold to the surrounding community.

Dr. Armen received his Ph.D. in Physical Chemistry from the City University of New York. He arrived in the United States in 1970 at age seventeen, speaking limited English, and worked as a messenger and kitchen hand before finding his path. That journey — from new immigrant to scientist, entrepreneur, and philanthropist — informs his analysis of the world.

Garo Armen's worldview accounts for the social, geopolitical, and market trends that he has navigated throughout his career, while holding onto the values of his humble origins, and never losing sight of the human consequences that results from tectonic global change.